Translations:GLP-1 receptor agonist/3/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 21:59, 5 February 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (GLP-1 receptor agonist)
GLP-1 agonists were initially developed for [[type 2 diabetes]]. The 2022 [[American Diabetes Association]] standards of medical care recommend GLP-1 agonists as a first line therapy for type 2 diabetes, specifically in patients with [[atherosclerotic cardiovascular disease]] or [[obesity]]. The drugs were also noted to reduce food intake and body weight significantly, and some have also been approved to treat obesity in the absence of diabetes. They are also in development for other indications, such as [[non-alcoholic fatty liver disease]], [[polycystic ovary syndrome]], and diseases of the [[reward system]] such as addictions.

GLP-1 agonists were initially developed for type 2 diabetes. The 2022 American Diabetes Association standards of medical care recommend GLP-1 agonists as a first line therapy for type 2 diabetes, specifically in patients with atherosclerotic cardiovascular disease or obesity. The drugs were also noted to reduce food intake and body weight significantly, and some have also been approved to treat obesity in the absence of diabetes. They are also in development for other indications, such as non-alcoholic fatty liver disease, polycystic ovary syndrome, and diseases of the reward system such as addictions.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:GLP-1_receptor_agonist/3/en&oldid=110953"